Similar articles

• [Use of Sanoserum P.A. in the treatment of Pseudomonas aeruginosa infection].

  Philips R, Philips I. Philips R, et al. Klin Oczna. 1987 Apr;89(4):158-9. Klin Oczna. 1987. PMID: 3118093 Polish. No abstract available.
• [The efficacy of specific plasma in the therapy of newborn infants with a Pseudomonas aeruginosa surgical infection].

  Samsygin SA, Ovchinnikova EA, Krasovskaia TV, Dolgina EN, Ekk ND. Samsygin SA, et al. Khirurgiia (Mosk). 1992 Nov-Dec;(11-12):61-5. Khirurgiia (Mosk). 1992. PMID: 1294799 Russian.
• [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].

  Minukhin VV, Tsyganenko AIa. Minukhin VV, et al. Antibiot Khimioter. 1989 Apr;34(4):282-6. Antibiot Khimioter. 1989. PMID: 2502083 Russian.
• [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].

  Moss RB. Moss RB. Infusionsther Transfusionsmed. 1993 Apr;20 Suppl 1:42-6; discussion 47. Infusionsther Transfusionsmed. 1993. PMID: 8499750 Review. German.
• Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update.

  Vincent JL. Vincent JL. Future Microbiol. 2014;9(4):457-63. doi: 10.2217/fmb.14.10. Future Microbiol. 2014. PMID: 24810345 Review.